利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.031 秒)

    MEDICAMENTS
    1.
    发明申请
    MEDICAMENTS 审中-公开
    药物

    公开(公告)号：US20100137201A1

    公开(公告)日：2010-06-03

    申请号：US12306501

    申请日：2007-06-29

    申请人： Mark W. J. Ferguson ,  Hugh G. Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nicholas Goldspink

    发明人： Mark W. J. Ferguson ,  Hugh G. Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nicholas Goldspink

    IPC分类号： A61K38/17 ,  C07K14/435

    CPC分类号： A61K38/1709

    摘要： There is provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention, reduction or inhibition of scarring. There is also provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention and/or treatment of a fibrotic disorder. Further aspects relate to methods by which scarring may be prevented, reduced or inhibited, and by which fibrotic disorders may be prevented and/or treated. Therapeutically effective amounts of WNT5A, or its fragments or derivatives, that may be used in the medicaments or methods of the invention are also provided.

    摘要翻译： 提供了WNT5A或其治疗有效的片段或衍生物在制备用于预防，减少或抑制瘢痕形成的药物中的用途。 还提供了WNT5A或其治疗有效的片段或衍生物在制备用于预防和/或治疗纤维化病症的药物中的用途。 另外的方面涉及可以预防，减少或抑制瘢痕形成的方法，以及可以通过哪些可以预防和/或治疗纤维化疾病。 还提供了可用于本发明的药物或方法中的治疗有效量的WNT5A或其片段或衍生物。

    MEDICAMENTS AND METHODS FOR PROMOTING WOUND CONTRACTION
    2.
    发明申请
    MEDICAMENTS AND METHODS FOR PROMOTING WOUND CONTRACTION 审中-公开
    促进创伤契约的药物和方法

    公开(公告)号：US20100144690A1

    公开(公告)日：2010-06-10

    申请号：US12520496

    申请日：2007-12-23

    申请人： Mark W. J. Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

    发明人： Mark W. J. Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

    IPC分类号： A61K31/57 ,  A61K31/575 ,  A61P17/02

    CPC分类号： A61K31/57 ,  A61K31/575 ,  A61K31/58

    摘要： Provided are antagonists of FXR activity for use as medicament for the prevention, reduction or inhibition of scarring. This use may preferably be to prevent, reduce or inhibit scarring formed on healing of wounds. The invention also provides corresponding methods of treatment. Preferred antagonists of FXR activity include guggulsterone (Z); guggulsterone (E); a scalarane; 80-574; and a 5α-bile alcohol. In advantageous embodiments, up to 32 μM of the antagonist of FXR activity may be provided per linear cm of wound, or cm2 of a wound or fibrotic disorder, over a 24 hour period in order to inhibit scarring.

    摘要翻译： 提供FXR活性的拮抗剂，用作预防，减少或抑制瘢痕形成的药物。 该用途可以优选地是防止，减少或抑制伤口愈合时形成的瘢痕形成。 本发明还提供相应的治疗方法。 优选的FXR活性拮抗剂包括苦瓜酮（Z）; 格鲁斯酮（E）; 一个标准 80-574; 和5α-胆汁醇。 在有利的实施方案中，为了抑制瘢痕形成，可以在24小时内每线性cm伤口或cm2的伤口或纤维化病症提供高达32μM的FXR活性拮抗剂。

    USE OF WNT3A FOR ACCELERATION OF WOUND HEALING
    3.
    发明申请
    USE OF WNT3A FOR ACCELERATION OF WOUND HEALING 审中-公开
    使用WNT3A加速治疗

    公开(公告)号：US20100286055A1

    公开(公告)日：2010-11-11

    申请号：US12527185

    申请日：2008-02-14

    申请人： Mark W. J. Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

    发明人： Mark W. J. Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

    IPC分类号： A61K38/17 ,  A61P17/02

    CPC分类号： A61K38/17

    摘要： Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for accelerating wound healing. Also provided is a method of accelerating wound healing, the method comprising providing a therapeutically effective amount of WNT3 A, or a therapeutically effective fragment or derivative thereof, to a site where wound healing is to be accelerated. The medicaments and methods of the invention may be of particular use in accelerating the healing of skin wounds.

    摘要翻译： 提供用作加速伤口愈合的药物的WNT3A或其治疗有效的片段或衍生物。 还提供了加速伤口愈合的方法，该方法包括向受伤愈合加速的部位提供治疗有效量的WNT3A或其治疗有效的片段或衍生物。 本发明的药物和方法可以特别用于加速皮肤伤口的愈合。

    SECRETED FRIZZLED RELATED PROTEIN 3 FOR USE IN THE INHIBITION OF SCARRING
    4.
    发明申请
    SECRETED FRIZZLED RELATED PROTEIN 3 FOR USE IN THE INHIBITION OF SCARRING 审中-公开
    分泌的相关蛋白3用于抑制瘢痕形成

    公开(公告)号：US20100261659A1

    公开(公告)日：2010-10-14

    申请号：US12596332

    申请日：2008-04-17

    申请人： Mark W. J. Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

    发明人： Mark W. J. Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

    IPC分类号： A61K38/17 ,  A61P17/02

    CPC分类号： A61K38/177

    摘要： Provided is secreted Frizzled Related Protein 3 (sFRP3), or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring. The scarring may be associated with the healing of a wound, or with a fibrotic disorder. The scarring may be associated with surgical wounds. The scarring may be scarring of the skin. The medicament may be a topical medicament, and may be suitable for local injection. Also provided is a method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of sFRP3, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition.

    摘要翻译： 提供分泌的卷曲相关蛋白3（sFRP3）或其治疗有效的片段或衍生物，用作预防，减少或抑制瘢痕形成的药物。 瘢痕形成可能与伤口愈合或纤维化疾病有关。 瘢痕形成可能与外科伤口有关。 瘢痕可能是皮肤疤痕。 药物可以是局部药物，并且可以适用于局部注射。 还提供了预防，减少或抑制瘢痕形成的方法，所述方法包括向需要这种预防，减少或抑制的患者施用治疗有效量的sFRP3或其治疗有效的片段或衍生物。

    METHODS FOR INHIBITION OF SCARRING
    5.
    发明申请
    METHODS FOR INHIBITION OF SCARRING 审中-公开
    抑制扫描的方法

    公开(公告)号：US20110166067A1

    公开(公告)日：2011-07-07

    申请号：US13003760

    申请日：2008-12-11

    申请人： Mark William James Ferguson ,  Sharon O'Kane ,  Nicholas Occleston ,  Nicholas Goldspink ,  Kerry Nield ,  Abdul Sattar ,  James Bush

    发明人： Mark William James Ferguson ,  Sharon O'Kane ,  Nicholas Occleston ,  Nicholas Goldspink ,  Kerry Nield ,  Abdul Sattar ,  James Bush

    IPC分类号： A61K38/18 ,  C07K14/495 ,  A61P17/02 ,  A61P9/00

    CPC分类号： A61K38/1841

    摘要： The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment TGF-β3 is provided to each centimetre of a wound margin or each centimetre of a site at which a wound is to be formed in a first therapeutically effective amount; and in a subsequent incidence of treatment TGF-β3 is provided to each centimetre of wound margin in a larger therapeutically effective amount of TGF-β3. The incidences of treatment occur between 8 hours and 48 hours apart from one another. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.

    摘要翻译： 本发明提供使用TGF-β3抑制人类瘢痕形成的新治疗方法，以及用于抑制人瘢痕形成的新用途的TGF-β3。 在治疗的第一次发生中，TGF-β1被提供给每个厘米的伤口边缘或每厘米的伤口以第一治疗有效量形成的部位; 并且在随后的治疗发生中，在更大的治疗有效量的TGF-βb中，向伤口边缘的每厘米提供TGF-β; 3。 治疗的发生发生在彼此之间8小时至48小时之间。 TGF-β可以通过皮内注射来提供。 还提供了选择用于抑制与人类伤口愈合相关的瘢痕形成的适当治疗方案的试剂盒和方法。

    MEDICAMENTS AND METHODS FOR INHIBITION OF NON-OCULAR SCARRING
    6.
    发明申请
    MEDICAMENTS AND METHODS FOR INHIBITION OF NON-OCULAR SCARRING 审中-公开
    用于抑制非眼科疾病的药物和方法

    公开(公告)号：US20100204248A1

    公开(公告)日：2010-08-12

    申请号：US12671005

    申请日：2008-07-31

    申请人： Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

    发明人： Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

    IPC分类号： A61K31/52 ,  C07D473/38 ,  A61P17/02

    CPC分类号： A61K31/407 ,  A61K31/52

    摘要： Provided is the use of an agonist of a member of the nuclear hormone receptor NR4A subgroup in the manufacture of a medicament for the prevention, reduction or inhibition of scarring in a non-ocular tissue. Also provided is a method of preventing, reducing or inhibiting scarring in a non-ocular tissue, the method comprising administering a therapeutically effective amount of an agonist of a member of the nuclear hormone receptor NR4A subgroup to a patient in need of such prevention, reduction or inhibition. The NR4A agonist may be 6-mercaptopurine. The medicaments and methods may preferably be used to prevent, reduce or inhibit scarring in the skin. The medicaments and methods of the invention may be used to accelerate healing of wounds.

    摘要翻译： 提供了核激素受体NR4A亚组的成员的激动剂在制备用于预防，减少或抑制非眼组织中的瘢痕形成的药物中的用途。 还提供了一种在非眼组织中预防，减少或抑制瘢痕形成的方法，所述方法包括向需要这种预防，还原的患者施用治疗有效量的激素受体NR4A亚组成员的激动剂 或抑制。 NR4A激动剂可以是6-巯基嘌呤。 药物和方法可优选用于预防，减少或抑制皮肤中的瘢痕形成。 本发明的药物和方法可用于加速伤口愈合。

    WNT3A FOR INHIBITION OF SCARRING
    8.
    发明申请
    WNT3A FOR INHIBITION OF SCARRING 审中-公开
    WNT3A用于抑制扫描

    公开(公告)号：US20110212897A1

    公开(公告)日：2011-09-01

    申请号：US12527182

    申请日：2008-02-14

    申请人： Mark William James Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

    发明人： Mark William James Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

    IPC分类号： C07K14/435 ,  A61K38/17 ,  A61P17/02

    CPC分类号： A61K38/1709

    摘要： Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring. Also provided is a method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of WNT3A, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition. The methods and medicaments of the invention are suitable for use in the prevention, reduction or inhibition of scarring arising as a result of healing of a wound, or scarring associated with a fibrotic disorder. The methods and medicaments disclosed are of particular use in preventing, reducing or inhibiting scarring of the skin.

    摘要翻译： 提供用作预防，减少或抑制瘢痕形成的药物的WNT3A或其治疗有效的片段或衍生物。 还提供了预防，减少或抑制瘢痕形成的方法，所述方法包括向需要这种预防，减少或抑制的患者施用治疗有效量的WNT3A或其治疗有效的片段或衍生物。 本发明的方法和药物适用于预防，减少或抑制由于伤口愈合或与纤维化病症相关的瘢痕形成引起的瘢痕形成。 所公开的方法和药物特别用于预防，减少或抑制皮肤瘢痕形成。

    Medicaments and Methods for Inhibition of Scarring
    9.
    发明申请
    Medicaments and Methods for Inhibition of Scarring 审中-公开
    药物和抑制疤痕的方法

    公开(公告)号：US20110082171A1

    公开(公告)日：2011-04-07

    申请号：US12995900

    申请日：2009-06-02

    申请人： Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nick Goldspink

    发明人： Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nick Goldspink

    IPC分类号： A61K31/437 ,  A61P17/02

    CPC分类号： A61K31/437

    摘要： Provided is the use of an agonist of a GABAA receptor for use in the prevention, reduction or inhibition of scarring formed on healing of a wound. Also provided is a method of preventing, reducing or inhibiting scarring formed on healing of a wound, in which a therapeutically effective amount of an agonist of a GABAA receptor is administered to a patient in need of such prevention, reduction or inhibition. The GABAA receptor agonist used may be an agonist specific to the GABAA receptor, such as Gaboxadol (7-tetra hydroisoxazolo[5,4-c]pyridin-3-ol), or a pharmaceutically acceptable salt thereof. The scarring to be prevented, reduced or inhibited may be scarring formed on healing of a wound of the dermis.

    摘要翻译： 提供了用于预防，减少或抑制伤口愈合时形成的瘢痕形成的GABA A受体激动剂的用途。 还提供了预防，减少或抑制伤口愈合时形成的瘢痕形成的方法，其中向需要这种预防，减少或抑制的患者施用治疗有效量的GABA A受体激动剂。 所使用的GABA A受体激动剂可以是对GABA A受体特异的激动剂，例如加波沙朵（7-四氢异恶唑并[5,4-c]吡啶-3-醇））或其药学上可接受的盐。 要防止，减少或抑制的疤痕可能在真皮的伤口愈合时形成瘢痕。